Table of Contents
For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables long-term commercial success.
At Adragos Pharma’s Maisons-Alfort facility in France, that combination is at the core of the site’s proposition.
Maisons-Alfort is a commercial-scale sterile manufacturing facility specialising in PFS manufacturing as well as liquid and lyophilised vial production. Built to support global programmes, the site brings together aseptic filling, industrial freeze-drying, visual inspection, packaging and logistics within one integrated environment. Supported by robust GMP systems and controlled aseptic operations, Maisons-Alfort is designed to deliver the quality, compliance and continuity of supply that pharmaceutical and biotech companies expect from a trusted manufacturing partner.
A strong platform for commercial-scale PFS manufacturing
At the heart of Maisons-Alfort is a clear strength in PFS manufacturing.
The site has been developed to support prefilled syringe production at commercial scale, with the infrastructure and operational model required for high-volume sterile manufacturing. This makes Maisons-Alfort particularly relevant for companies looking for a partner that can support commercial supply with consistency, control and reliability.
For decision-makers evaluating outsourcing options, this matters because PFS manufacturing is not simply a technical capability — it is also a supply and quality commitment. At commercial stage, the manufacturing partner must be able to combine throughput with discipline, and operational efficiency with a strong quality environment. Maisons-Alfort is positioned to do exactly that, with prefilled syringes representing a core focus of the site.
Supporting sterile vial manufacturing alongside PFS expertise
In addition to its position in PFS manufacturing, Maisons-Alfort also supports liquid and lyophilised vial production.
This combination gives customers access to a site that can serve multiple sterile dosage form needs within one commercial manufacturing environment. For companies building or expanding product portfolios, that broader capability can bring practical advantages, from operational simplification to stronger alignment across production and supply planning.
By combining PFS manufacturing and sterile vial expertise on one site, Maisons-Alfort offers a more integrated proposition for customers seeking flexibility, quality and scalability in sterile drug product manufacturing.
Built around quality, compliance and control
In sterile manufacturing, confidence comes from the operating model behind the process.
Maisons-Alfort has been designed to operate within controlled aseptic environments and to meet stringent GMP expectations. Supported by technologies such as active RABS and integrated CIP/SIP systems, the site reflects a strong focus on process control, product protection and compliance.
For external partners, this is an important part of the value proposition. Commercial sterile manufacturing requires more than the ability to produce. It requires a facility culture and infrastructure that can sustain quality over time, support regulatory expectations and reduce operational risk. Maisons-Alfort has been positioned with that responsibility in mind.
More than a fill-finish site
One of the strengths of Maisons-Alfort is that it offers more than aseptic filling alone.
The site includes integrated visual inspection, packaging and assembly, and storage and logistics capabilities, helping create a more complete manufacturing and supply platform. This broader service model supports product quality, operational efficiency and readiness for commercial supply.
For customers, that means access to a partner that can contribute not only to sterile production itself, but also to the downstream activities that influence how reliably products move through the final stages of manufacturing and into the supply chain.
This is especially relevant for procurement and BD audiences, who often assess a site not just on isolated production capabilities, but on how effectively the wider operational model supports supply continuity and programme execution.
Packaging and logistics that support commercial readiness
Commercial success in sterile manufacturing depends heavily on what happens around production, not just within it.
Maisons-Alfort benefits from dedicated packaging capabilities designed to support a range of product presentations, including more complex requirements where needed. Combined with a robust logistics model and warehousing support, this helps the site operate as a commercially ready platform rather than a narrow technical asset.
This integrated approach is increasingly important for pharma and biotech companies seeking outsourcing partners. The more seamlessly manufacturing, inspection, packaging and logistics work together, the easier it becomes to support consistency, responsiveness and reliable delivery over time.
Designed to support global programmes
Maisons-Alfort operates under EU GMP and is supported by a strong compliance framework aligned with the expectations of regulated markets. The site is positioned to support global regulatory programmes and reflects the audit readiness and operational discipline required in modern sterile manufacturing.
For companies planning commercial supply, this creates added confidence. Manufacturing partners are expected to do more than deliver technical execution — they must also bring the structure, quality mindset and regulatory readiness needed to support sustained market supply.
That is why Maisons-Alfort should be understood not only as a sterile manufacturing site, but as a commercial platform designed to help customers move forward with confidence.
A compelling partner for PFS manufacturing and sterile supply
What makes Maisons-Alfort stand out is the combination of capabilities brought together in one site: commercial-scale PFS manufacturing, sterile vial production, integrated inspection, packaging, logistics and a strong quality framework.
For pharma and biotech decision-makers, this creates a compelling proposition. The site is built to support the priorities that matter most at commercial stage — quality, control, reliability and continuity of supply — while offering the operational scale required for long-term programmes.
As part of Adragos Pharma’s network, Maisons-Alfort strengthens the company’s ability to support customers with dependable sterile manufacturing solutions tailored to commercial needs.
